PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Catalyst Pharmaceuticals, Inc. (CPRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS14888U1016
CUSIP14888U101
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.95B
EPS$0.56
PE Ratio29.45
Revenue (TTM)$411.35M
Gross Profit (TTM)$160.02M
EBITDA (TTM)$114.04M
Year Range$11.09 - $17.50
Target Price$27.29
Short %8.12%
Short Ratio5.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Catalyst Pharmaceuticals, Inc.

Popular comparisons: CPRX vs. CL, CPRX vs. XPEL, CPRX vs. TPL, CPRX vs. BMRN, CPRX vs. AADI, CPRX vs. MOH, CPRX vs. ENSG, CPRX vs. SPY, CPRX vs. FLGT, CPRX vs. QQQ

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Catalyst Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%150.00%200.00%250.00%300.00%December2024FebruaryMarchAprilMay
160.16%
282.81%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Catalyst Pharmaceuticals, Inc. had a return of -5.59% year-to-date (YTD) and 36.93% in the last 12 months. Over the past 10 years, Catalyst Pharmaceuticals, Inc. had an annualized return of 22.80%, outperforming the S&P 500 benchmark which had an annualized return of 10.76%.


PeriodReturnBenchmark
Year-To-Date-5.59%11.21%
1 month4.96%4.60%
6 months12.87%16.35%
1 year36.93%27.79%
5 years (annualized)34.50%13.43%
10 years (annualized)22.80%10.76%

Monthly Returns

The table below presents the monthly returns of CPRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-14.34%11.32%-0.56%-5.58%-5.59%
2023-16.72%-1.48%8.65%-3.98%-27.45%16.36%2.90%1.52%-16.74%6.16%16.28%16.49%-9.62%
2022-14.92%35.42%6.28%-8.08%-5.51%-2.64%46.08%32.23%-5.24%8.11%20.91%10.91%174.74%
20218.98%6.87%18.51%-0.65%20.74%3.98%1.57%-5.65%-3.81%11.32%18.64%-3.29%102.69%
20209.60%2.43%-8.55%23.12%-9.07%7.19%-6.93%-23.72%-9.45%-0.00%23.23%-8.74%-10.93%
201931.25%15.48%75.26%12.55%-39.02%9.71%29.95%23.45%-13.80%-10.92%-1.90%-19.18%95.31%
2018-13.30%-5.90%-25.08%17.15%37.14%-18.75%-7.37%16.61%12.17%-21.16%-14.93%-24.26%-50.90%
20176.67%0.89%72.57%-5.64%15.22%30.19%6.52%-6.46%-8.36%13.49%50.35%-9.07%272.38%
2016-24.08%-43.55%11.43%-41.88%-9.56%15.45%1.41%40.28%7.92%-3.67%3.81%-3.67%-57.14%
201522.90%3.01%15.16%-27.02%25.00%4.56%19.61%-26.52%-17.36%5.33%-14.08%-9.76%-17.51%
20140.00%14.87%0.89%-7.96%5.77%15.00%-10.28%40.97%3.75%-10.54%-10.77%12.08%52.31%
201319.54%-11.92%7.03%54.02%17.88%0.67%45.09%49.23%57.22%-46.89%6.17%13.37%348.28%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of CPRX is 70, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of CPRX is 7070
CPRX (Catalyst Pharmaceuticals, Inc.)
The Sharpe Ratio Rank of CPRX is 7171Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 6767Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 6565Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 7575Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 7373Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


CPRX
Sharpe ratio
The chart of Sharpe ratio for CPRX, currently valued at 0.80, compared to the broader market-2.00-1.000.001.002.003.004.000.80
Sortino ratio
The chart of Sortino ratio for CPRX, currently valued at 1.33, compared to the broader market-4.00-2.000.002.004.006.001.33
Omega ratio
The chart of Omega ratio for CPRX, currently valued at 1.17, compared to the broader market0.501.001.502.001.17
Calmar ratio
The chart of Calmar ratio for CPRX, currently valued at 0.77, compared to the broader market0.002.004.006.000.77
Martin ratio
The chart of Martin ratio for CPRX, currently valued at 3.08, compared to the broader market-10.000.0010.0020.0030.003.08
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.52, compared to the broader market-2.00-1.000.001.002.003.004.002.52
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.56, compared to the broader market-4.00-2.000.002.004.006.003.56
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.44, compared to the broader market0.501.001.502.001.44
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.04, compared to the broader market0.002.004.006.002.04
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.59, compared to the broader market-10.000.0010.0020.0030.009.59

Sharpe Ratio

The current Catalyst Pharmaceuticals, Inc. Sharpe ratio is 0.80. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Catalyst Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
0.80
2.52
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Catalyst Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-40.00%-30.00%-20.00%-10.00%0.00%December2024FebruaryMarchAprilMay
-24.61%
-0.31%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Catalyst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Catalyst Pharmaceuticals, Inc. was 94.25%, occurring on Nov 12, 2012. Recovery took 1717 trading sessions.

The current Catalyst Pharmaceuticals, Inc. drawdown is 24.61%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.25%Feb 2, 20071429Nov 12, 20121717Sep 10, 20193146
-64.87%Sep 12, 2019128Mar 16, 2020424Nov 17, 2021552
-45.37%Jan 17, 202392May 26, 2023
-38.21%Nov 10, 200649Jan 24, 20075Jan 31, 200754
-28.72%Nov 18, 202148Jan 27, 202211Feb 11, 202259

Volatility

Volatility Chart

The current Catalyst Pharmaceuticals, Inc. volatility is 9.96%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%December2024FebruaryMarchAprilMay
9.96%
3.10%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items